PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER
Prostate cancer treatment & diagnosis
Primary Objectives to determine whether SBRT can be shown to be superior to hypofractionated IMRT in terms of GU and GI toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel HRQOL.
Dr. Michael I. Ghilezan
Radiation OncologistWorks at 4 centers.
Dr. Larry L. Kestin
Radiation OncologistWorks at 3 centers.
Dr. Kay T. Miller
Radiation OncologistClarkston (Radiation oncology)
Dr. Frank A. Vicini
MD, FACR, FASTRO
Radiation oncologistWorks at 3 centers.